Copy
Welcome to our monthly Newsbites!
Jump directly to:


HOT   Launch FLEXcyte 96

NEWS   User Meetings, Sarah Tahir, win an iPad

TOPIC  Cardiac NaV-Late current
  HOT    
Launch FLEXcyte 96

Launch of the FLEXcyte 96

 
On September 9th 2019 we launched the FLEXcyte 96 instrument. The FLEXcyte 96 comes as an add-on for the CardioExcyte 96. With less than 10 μm in thickness and sophisticated surface modification, the polydimethylsiloxane (PDMS) membranes of the FLEXcyte 96 disposable plates offer physiological elasticity of native human heart tissue and strong mechanical support. While being deflected by the weight of the culture medium, rhythmic contraction of the cardiomyocytes lift the membranes in the 96-well upwards. By measuring the changes in deflection, the mechanical stress can be calculated. Read the full press release hereVisit the product page here.

FLEXcyte 96 Video

Watch this video and see how Laura uses the FLEXcyte 96 to analyze the contraction force of human iPSC-derived cardiomyocytes by cultivating the cells on a well-defined, flexible substrate with less than 10 μm in thickness.
Watch the video here.

FLEXcyte 96 Brochure

The FLEXcyte 96 brings in vitro contraction force measurements of cardiac cells to a new dimension. This unique technology allows for recordings in a native-like environment close to mechanical conditions of the heart.  
Read the brochure here

FLEXcyte 96 White Paper

"Higher throughput in vitro cardiac contractility recordings under physiological mechanical conditions" (Sonja Stölzle-Feix et al.)
• Translatability of data obtained from hiPSC-CMs to human physiology is the subject of current scientific discussion • Contractility data derived from hiPSC-CMs in an environment that reflects the mechanical properties of real human cardiac tissue in a higher throughput format (FLEXcyte 96) is physiologically relevant • Example data on commercially available cell types with the FLEXcyte 96 system show a high degree of consistency with clinical data.
Download the white paper here.
  NEWS    
User Meetings, Sarah Tahir, win an iPad

Win an iPad


Take a short survey and win an iPad. Prize draw will take place during the User Meeting Dinner in Munich at the 17th of October. Click here.

Latest Publications


SyncroPatch 384i:
Rapid characterisation of hERG channel kinetics I: using an automated high-throughput system
Lei CL. et al., Biophys: J (2019) - Download here.

SyncroPatch 384i:
Rapid Characterization of hERG Channel Kinetics II: Temperature Dependence
Lei CL. et al., Biophys: J (2019) - Download here.

Patchliner:
A Kinetic Map of the Homomeric Voltage-Gated Potassium Channel (Kv) Family.
Ranjan R. et al., (2019) Front. Cell. Neurosci. - Download here.


CardioExcyte 96:
Downregulation of miR-146a Contributes to Cardiac Dysfunction Induced by the Tyrosine Kinase Inhibitor Sunitinib.
Shen L. et al., Frontiers in Pharmacology (2019) - Download here.


CardioExcyte 96:
Pharmacological enhancement of repolarization reserve in human induced pluripotent stem cells derived cardiomyocytes.
Treat J.A. et al., (2019) Biochem. Pharmacol. - Download here.


SURFE2R ONE (predecessor  model of SURFE2R N1):
Phosphatidylserine flipping by the P4-ATPase ATP8A2 is electrogenic.
Tadini-Buoninsegni F. et al., (2019) PNAS - Download here.

Port-a-PatchVesicle Prep Pro and Orbit mini:
Electrophysiological Characterization of Transport Across Outer Membrane Channels from Gram-Negative Bacteria in Their Native Environment.
Wang J. et al., (2019) ChemRxiv (Pre-publication) - Download here.

Port-a-Patch and Vesicle Prep Pro:
Temporin L and aurein 2.5 have identical conformations but subtly distinct membrane and antibacterial activities.
Manzo G. et al., (2019) Nature Scientific Reports - Download here.

Vesicle Prep Pro:
Barcoding biological reactions with DNA-functionalized vesicles.
Peruzzi J.A. et al., (2019) BioRxiv (Pre-publication) - Download here.

Vesicle Prep Pro:
A Fusion Peptide in the Spike Protein of MERS Coronavirus.
Alsaadi E.A.J. et al., (2019) Viruses - Download here.

 
Vesicle Prep Pro:
Fluorescent Artificial Receptor-Based Membrane Assay (FARMA) for Spatiotemporally Resolved Monitoring of Biomembrane Permeability.
Biedermann F. et al., (2019) ChemRxiv (Pre-publication) - Download here.

We love Diversity at Nanion


Meet Sarah Tahir from our USA branch. Sarah was born in Saudi Arabia but grew up in New Jersey. Extraordinarily friendly and hardworking, Sarah is excited to share her story with you! Read Sarah's interview here.

10th User Meeting Munich


The meeting is rapidly approaching, don`t miss out: registration is free. Our Annual User Meeting 2019 will be held on October 17th - 18th in Munich at  Nanion's headquarters.

Download the preliminary agenda here
Spaces are limited, register here.

Join us for the Nanion Sponsored Session at SPS 2019


Session focuses on HTS approaches for studying cardiac ion channels and iPSC-CMs in research, screening, and risk assessment. Find out more here

Session Title: Future Technologies in Safety Pharmacology and Drug Discovery
Date: Tuesday, September 24th, 12:30-13:30
Meeting Room: Room 119
Free lunch provided!

Nanion TWMU Ion Channel Forum


The Meeting will be held at the Tokyo Woman's Medical University in October 3rd - 4th.
You are cordially invited to join us! Find out more information here.

Mark Your Calendar


23. - 26. September 2019:
Safety Pharmacology Annual Meeting 2019
(Barcelona, Spain). Meet Sonja Stölzle-Feix, Elena Dragicevic (Nanion Germany) and Ronald Knox, Rodolfo J. Haedo (Nanion USA).

30. September - 02. October 2019:
98th Meeting of The German Physiological Society
(Ulm, Germany). Meet Elena Dragicevic, Patrick Mumm and Mary Kasoha.

02. - 05. October 2019:
7th International Workshop on Structure and Function of Ion Channels and Transporters (SFICT)
(Genoa, Italy). Meet Andrea Brüggemann.

19. - 23. October 2019:
Neuroscience 2019
(Chicago, USA). Meet Elena Dragicevic and Maria Barthmes.

27. October - 01. November 2019:
Calcium Signalling Conference
(Fez, Morocco). Meet Elena Dragicevic and Maria Barthmes.

Snapshot of the Month

 
The Port-a-Patch mini on it's first big trip! After attending the Microelectrode Techniques workshop for Cell Physiology in Plymouth, Nanion's András Horváth stopped by Dr. Craig Beall's lab at the University of Exeter to demonstrate the Port-a-Patch mini. A large crowd of students and post docs were interested in seeing live recordings from astrocytes! Thanks to Dr. Craig Beall for hosting András. Get in touch today to arrange your demo of the Port-a-Patch mini!
  TOPIC    
NaV-Late current: implications for cardiac safety testing
NaV1.5 - the cardiac sodium channel 

The voltage-gated Na+ channel 1.5 (NaV1.5) is encoded by the SCN5A gene and is responsible for the rising phase of the cardiac action potential. The NaV1.5 channel is comprised of a pore-forming α subunit and auxillary β subunits. When the cardiac cell membrane depolarizes, NaV1.5 opens for a short time allowing an influx of Na+ ions resulting in the upstroke of the action potential. During the action potential, these channels can recover from inactivation and re-open resulting in a sustained current termed INa-Late. Although this current is substantially smaller than the peak Na+ current, it is active during the plateau phase and therefore contributes to AP morphology. There is a growing body of evidence that increased INa-Late can have a pathophysiological role in acquired heart diseases such as myocardial ischemia and heart failure. INa-Late is elevated in several pathological conditions which could result in Na+-overload in these cells. A number of loss or gain-of-function mutations in the SCN5A gene have been identified which lead to changes in the magnitude or duration of INa-Peak or INa-Late resulting in fatal arrhythmias.
NaV1.5 as a drug target and in safety pharmacology testing

INa-Late is pathalogically increased in genetic and acquired heart disease and is, therefore, a potential drug target to treat cardiac disorders such as angina, heart failure and arrhythmia. Indeed, ranolazine, a selective blocker of the INa-Late current, is a clinically approved anti-ischemic drug.

The channel is also an important target in safety pharmacology as enhancement of INa-Late is pro-arrhythmic. Therefore, INa-Late is one of the ion channel currents included in the comprehensive in vitro pro-arrhythmic assay (CiPA) initiative within the ion channel working group (ICWG) on automated patch clamp systems.

INa-Late Recommended Assays, Cell Lines and Literature


NaV1.5 expressed in cell lines or hiPSC-CMs can be recorded using APC instruments

Recommended assays:
  • SyncroPatch 384i (HTS patch clamp): external solution exchange; internal perfusion; temperature control
  • Patchliner (automated patch clamp): external solution exchange; internal solution exchange; temperature control; dynamic clamp
  • Port-a-Patch(automated patch clamp): external perfusion; internal perfusion; temperature control
  • Port-a-Patch mini (automated patch clamp)

Recommended cell lines:

Recommended hIPSC-CMs:

Read INa-Late Application Note and Poster from Icagen

Visit our website for more Application Notes!
Website
Nanion Twitter
Nanion Facebook
Nanion YouTube Channel
Nanion Email
Share Share
Share Share
Tweet Tweet
Forward Forward
Copyright © 2019 Nanion Technologies GmbH, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list